STX002
/ Styx Biotechnologies
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
STX002: A GPC3-targeted antibody-drug conjugate with potent and durable antitumor activity in preclinical models of hepatocellular carcinoma
(AACR 2026)
- "Collectively, these data support STX002 as a differentiated GPC3-targeted topo-I ADC with strong preclinical efficacy and translational potential. STX002 represents a promising therapeutic candidate for addressing the substantial unmet need in HCC and warrants advancement toward IND-enabling studies and clinical development."
ADC • Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3
1 to 1
Of
1
Go to page
1